H
HeartFlow
A non-invasive personalized cardiac test, physicians are able to make better care decisions for their patients with suspected coronary artery disease
About HeartFlow
HeartFlow is a health technology startup that operates in the cardiovascular care market. The company has developed a non-invasive cardiac test that provides detailed visualization of a patient's coronary arteries. This innovative technology assists physicians in creating more effective treatment plans for their patients, thereby making cardiovascular care safer and easier.
The company's primary clients are physicians and healthcare providers who are looking for safer, more efficient ways to diagnose and treat heart disease. HeartFlow's technology eliminates the need for invasive procedures, reducing both the risk to patients and the cost to healthcare providers.
HeartFlow's business model is based on the sale of its proprietary technology. The company's HeartFlow Analysis, which includes the FFRCT Analysis, RoadMap Analysis, Plaque Analysis, and HeartFlow Planner, has received FDA Clearance in the United States and is commercially available in the United States and the United Kingdom. It is also approved in Japan and Canada.
The company generates revenue by selling its technology to healthcare providers. It also likely earns income from ongoing service and maintenance contracts, as well as from updates and improvements to its technology.
In summary, HeartFlow is a health tech startup that has developed a non-invasive cardiac test to assist physicians in diagnosing and treating heart disease. The company operates in the cardiovascular care market and generates revenue from the sale of its technology and related services.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 2007
- Headquarters
- San Francisco, United States
- Listing
- IPO 2025
- Sector
- Biotech & Life Sciences
- Power Law
- Unicorn$1–10B valuation tierThoroughbred$100M+ revenue
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed3 investors entered at this stage
U.S. Venture Partners- HPHealthCor Partners
- EPEmergent Medical Partners
Series A1 investor entered at this stage
Series B and later10 investors entered at this stage
Capricorn Investment Group
Sandbox Industries
Panorama Point Partners
Rancilio Cube
Wellington Management
Baillie Gifford
Bain Capital Life SciencesJanus Henderson Investors
Hayfin Capital Management
Martis Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
across markets
Patents
88 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
Market sentiment
An AI-synthesised read of the highest-engagement posts about HeartFlow on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See HeartFlow on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.
